This content is PDF only. Please click on the PDF icon to access.
Abstract
Dibromomannitol (DBM) is one of the new chemotherapeutic compounds beneficial in the treatmentof chronic myelogenous leukemia. Investigation of the effects of the drug on the rat lens has demonstrated that it exerts a complex cytotoxic action on the epithelial population and, with prolonged administration, is cataractogenic in normal animals. The response to DBM only partially resembles that evoked by Myleran, a related drug known to induce cataracts in rats.